Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2009

View Archived Issues

Santen describes novel glucocorticoid receptor ligands for metabolic disorders, among others

Ipsen provides R&D pipeline update

Qnexa treatment improves glucose control in obese nondiabetic subjects

EpiCept to focus on Ceplene and discontinue drug discovery operations

MAP Pharmaceuticals presents update on phase III clinical trials of UDB and MAP-0004

ARYx reports results related to washout period from phase IIb trial of ATI-2042

Repros reports results from phase II trial of Proellex in endometriosis

Genta updates progress of phase III trial of Genasense in advanced melanoma

ASA-404 enters pivotal phase III second-line lung cancer trial

Cyclacel begins phase II sapacitabine trial in previously treated NSCLC patients

Idenix initiates proof-of-concept study of IDX-184 for hepatitis C virus

Lexicon initiates phase II LX-1031 trial in patients with irritable bowel syndrome

Neurobiological Technologies suspends Viprinex development

Protox commences placebo-controlled phase II BPH study

New gamma-secretase modulators reported in recent Schering-Plough patent

MacuCLEAR and Mystic collaborate on macular degeneration phase I/II trial

Merck & Co. discloses novel orexin receptor antagonists for insomnia

Novel modulators of sodium and/or calcium channels under development at Newron

First patient dosed in phase II NKTR-102 trial in ovarian cancer

Genta commences new trial for oral tesetaxel

e-Therapeutics reports positive phase IIa findings for antidepressant ETS-6103

Acorda provides 2009 pipeline update

Sunesis provides clinical update on voreloxin

Phosphatase inhibition may improve proteasome inhibitor treatment of leukemia

Targeting peptide enhances utility of liposomal anticancer agents in lung cancer xenografts

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...